<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623502</url>
  </required_header>
  <id_info>
    <org_study_id>STU2019-1061</org_study_id>
    <secondary_id>P50CA196516</secondary_id>
    <secondary_id>R35CA220449</secondary_id>
    <secondary_id>F31CA239330</secondary_id>
    <secondary_id>HHMI Investigator:DeBerardinis</secondary_id>
    <nct_id>NCT04623502</nct_id>
  </id_info>
  <brief_title>An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy</brief_title>
  <official_title>An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Howard Hughes Medical Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the metabolism of cancers involving the kidney,&#xD;
      including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use&#xD;
      different types of fuel to support tumor growth. This study uses specially labeled nutrient&#xD;
      tracers of compounds normally found circulating in the blood. The nutrients (glucose,&#xD;
      fructose, glutamine, acetate, and lactate) are also found in common foods. A nutrient tracer&#xD;
      will be given to the participants through an intravenous (IV) catheter during surgery or&#xD;
      biopsy, and blood will be collected every 30 minutes during the infusion to monitor safety&#xD;
      parameters and the nutrient tracers. The investigators will collect a tissue sample after the&#xD;
      completion of surgery. Participants not having an infusion will have their tissue collected&#xD;
      after surgery or biopsy.&#xD;
&#xD;
      Participation in this study will not change patient care. All patients will receive standard&#xD;
      of care treatment as determined by their doctors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to understand the metabolism of kidney cancers (renal cell&#xD;
      carcinomas and urothelial cell carcinomas involving the kidney) in patients. Metabolism is&#xD;
      the term used to describe how cells take up different nutrients and convert them to energy&#xD;
      and materials needed for cell growth. In cancer, metabolism is hijacked to support the needs&#xD;
      of cancer cells. Cancer cells can use multiple nutrients in the blood to fuel their growth,&#xD;
      but it is not known what materials cancer cells make with those nutrients in patients.&#xD;
&#xD;
      Many participants in this study will be infused with a 13C-labeled nutrient during their&#xD;
      surgery or biopsy. 13C means that the carbon in the nutrient is heavier than 12C carbons that&#xD;
      are the most abundant carbon atoms in nature. 13C carbons account for about 1% of natural&#xD;
      carbon atoms are not radioactive or harmful in any way. Using the tissue collected during or&#xD;
      after surgery and/or biopsy, the researchers can track how the heavier 13C carbons from the&#xD;
      infused nutrient are being used to make different materials that cancer cells need to grow.&#xD;
&#xD;
      The researchers hope to understand how kidney cancers change their metabolism to adapt, grow,&#xD;
      and survive in patients. The knowledge learned from this study will be used to support the&#xD;
      development of therapies that target metabolic adaptations, and the development of new&#xD;
      non-invasive imaging techniques that will improve the care and survival of future kidney&#xD;
      cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of 13C isotopologue distributions</measure>
    <time_frame>5 years</time_frame>
    <description>Tissue and blood samples will be analyzed for 13C isotopologue distributions (percent) in central carbon metabolites using mass spectrometry. This allows the Investigators to understand how different subtypes of kidney and urothelial cancers alter utilization of the 13C tracers.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Clear Cell Carcinoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Metastatic Kidney Cancer</condition>
  <condition>Metastatic Urothelial Carcinoma</condition>
  <condition>Papillary Renal Cell Carcinoma</condition>
  <condition>Chromophobe Renal Cell Carcinoma</condition>
  <condition>Fumarate Hydratase Deficiency</condition>
  <condition>Succinate Dehydrogenase-Deficient Renal Cell Carcinoma</condition>
  <condition>HLRCC</condition>
  <condition>Hereditary Leiomyomatosis and Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>13C-Glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>13C-Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>13C-Lactate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>13C-Glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>13C-Fructose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>13C-Glucose</intervention_name>
    <description>Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.</description>
    <arm_group_label>13C-Glucose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>13C-Acetate</intervention_name>
    <description>Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.</description>
    <arm_group_label>13C-Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>13C-Lactate</intervention_name>
    <description>Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.</description>
    <arm_group_label>13C-Lactate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>13C-Glutamine</intervention_name>
    <description>Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.</description>
    <arm_group_label>13C-Glutamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>13C-Fructose</intervention_name>
    <description>Patients in the 13C-fructose arm will receive an infusion of a 13C-fructose solution. In most cases, the fructose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.</description>
    <arm_group_label>13C-Fructose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have radiographic evidence of known or probable kidney or urothelial&#xD;
             cancer requiring surgical biopsy or excision.&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Subjects of all races and ethnic origins&#xD;
&#xD;
          -  The willingness to sign and ability to understand a written informed consent.&#xD;
&#xD;
          -  Patients participating in other clinical trials are eligible, and will be evaluated on&#xD;
             a case by case basis by the Principal Investigator, Dr. Vitaly Margulis, MD.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled or poorly controlled diabetes for patients receiving a 13C infusion&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Not a surgical candidate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vitaly Margulis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vitaly Margulis, MD</last_name>
    <phone>214-648-0567</phone>
    <email>vitaly.margulis@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ralph J DeBerardinis, MD, PhD</last_name>
    <phone>214-648-2585</phone>
    <email>ralph.deberardinis@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vitaly Margulis</last_name>
      <phone>214-648-0567</phone>
      <email>vitaly.margulis@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Vitaly Margulis</investigator_full_name>
    <investigator_title>Principal Investigator, Professor of Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Adenomyoepithelioma</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
    <mesh_term>Leiomyomatosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

